CC
MRNS

Corton Capital’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Corton Capital’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,999
Closed -$120K – 689
2023
Q4 		$120K Buy
+10,999
New +$82.4K 0.04% 534
2022
Q4 		– Sell
-12,736
Closed -$85K – 385
2022
Q3 		$85K Buy
+12,736
New +$78.4K 0.1% 245

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Corton Capital's MRNS Position: Q1 2024 in Review

Corton Capital sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2024, closing a stake of 10,999 shares — an estimated $120K sold.

Corton Capital first reported a position in MRNS in Q3 2022 and held it in 2 quarters. The position peaked at $120K in Q4 2023. 112 funds tracked by Wall St. Rank hold MRNS as of Q1 2024.

  • Corton Capital reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2024 after selling out during the quarter.
  • Corton Capital sold 10,999 Marinus Pharmaceuticals, Inc shares in Q1 2024, an estimated $120K.
  • Corton Capital first reported a position in Marinus Pharmaceuticals, Inc in Q3 2022 and held it in 2 quarters.
  • Corton Capital's Marinus Pharmaceuticals, Inc position peaked at $120K in Q4 2023.
  • 112 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2024.

Based on Corton Capital's 13F filing for Q1 2024, filed 15 May 2024.